SCHEMBL2076493

SCHEMBL2076493

O=C(Nc1cc(N2CCN(C3CCCC3)CC2)ncn1)c1ccccc1F

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
RAB9A P51151 5/20 0.51
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 3/20 0.48
ATM Q13315 2/20 0.48
HRH4 Q9H3N8 1/20 0.48
EGFR P00533 1/20 0.47
ERBB3 P21860 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PTPN11 Q06124 1/20 0.45
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.42
MCL1 Q07820 1/20 0.42
GAA P10253 1/20 0.42
USP2 O75604 1/20 0.42
GLA P06280 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190178 0.84 SMN1; SMN2 (0.47) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL4172542 0.84 PTPN11 (0.49) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL2075244 0.83 RAB9A (0.74) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2075301 0.83 SMN1; SMN2 (0.58) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2074070 0.79 HRH4 (0.56) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2075521 0.78 NAMPT (0.53) SMN1; SMN2ALDH1A1NPC1ATMHRH4
SCHEMBL2076138 0.77 HRH4 (0.54) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2075851 0.77 HRH4 (0.51) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2074954 0.76 HRH4 (0.55) SMN1; SMN2RAB9AALDH1A1NPC1ATM
SCHEMBL2074889 0.76 HRH4 (0.55) SMN1; SMN2RAB9AALDH1A1NPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902184-B2 Piperazinyl pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
CN-101448820-A Piperidinyl pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2009-06-03 CN disclosed
EP-2032554-A1 PIPERIDINYL PYRIMIDINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-03-11 EP disclosed
WO-2007137955-A1 PIPERIDINYL PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281921-A1 Piperidinyl pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281921-A1 Piperidinyl pyrimidine derivatives HRH2, P2RX5, P2RX3 SMN1; SMN2 4105/4885RAB9A 1046/4885ALDH1A1 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.